BCR-ABL⁺ acute myeloid leukemia: are we always dealing with a high-risk disease?

Blood Adv. 2018 Jun 26;2(12):1409-1411. doi: 10.1182/bloodadvances.2018015594.

Authors

Nina Rosa Neuendorff^{1

2}, Philipp Hemmati¹, Renate Arnold¹, Jana Ihlow¹, Bernd Dörken¹, Carsten Müller-Tidow², Jörg Westermann¹

Affiliations

¹ Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany; and.
² Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor
Diagnosis, Differential
Fusion Proteins, bcr-abl*
Humans
Leukemia, Myeloid, Acute / classification*
Leukemia, Myeloid, Acute / diagnosis
Retrospective Studies
Risk Assessment*

Substances

Biomarkers, Tumor
Fusion Proteins, bcr-abl